Eli Lilly and Company $LLY Stock Purchased by Tamar Securities LLC

Tamar Securities LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 18,808 shares of the company’s stock after buying an additional 447 shares during the period. Eli Lilly and Company accounts for 2.0% of Tamar Securities LLC’s portfolio, making the stock its 24th largest position. Tamar Securities LLC’s holdings in Eli Lilly and Company were worth $21,763,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. OPTIMAS CAPITAL Ltd purchased a new position in Eli Lilly and Company during the 3rd quarter valued at $1,641,000. Prudent Man Investment Management Inc. grew its position in Eli Lilly and Company by 18.3% in the 3rd quarter. Prudent Man Investment Management Inc. now owns 84 shares of the company’s stock valued at $97,000 after acquiring an additional 13 shares during the last quarter. May Hill Capital LLC increased its stake in Eli Lilly and Company by 4.2% in the third quarter. May Hill Capital LLC now owns 1,832 shares of the company’s stock worth $2,120,000 after purchasing an additional 74 shares during the period. Alps Advisors Inc. increased its stake in Eli Lilly and Company by 31.6% in the third quarter. Alps Advisors Inc. now owns 19,618 shares of the company’s stock worth $22,700,000 after purchasing an additional 4,707 shares during the period. Finally, Ashton Thomas Private Wealth LLC increased its stake in Eli Lilly and Company by 0.6% in the third quarter. Ashton Thomas Private Wealth LLC now owns 21,338 shares of the company’s stock worth $24,690,000 after purchasing an additional 119 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $17,020,770 in the last three months. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Up 0.5%

Shares of NYSE LLY opened at $1,372.15 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The business has a fifty day simple moving average of $1,215.24 and a two-hundred day simple moving average of $1,101.16. The firm has a market cap of $1.29 trillion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 1.69 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same period in the prior year, the business earned $7.02 EPS. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. Analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LLY. Scotiabank boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. TD Cowen reissued a “buy” rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $1,650.00 target price on shares of Eli Lilly and Company in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.